DYN
Dyne Therapeutics, Inc.
Healthcare · Biotechnology · NMS
$17.04
Data: 2026-05-28
✗ ETHICAL FAIL

Unknown MOAT
MODERATE
Data Confidence: 71.4%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$3.0B
Total market value of the company
Trailing P/E
N/A
Forward P/E
-6.09
Based on estimated future earnings — lower means cheaper
Rev Growth
N/A
Year-over-year revenue change
Profit Margin
0.0%
How much profit the company keeps from each dollar of revenue
ROE
-58.9%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$39.50
+132% from current price — median analyst estimate
Recommendation
STRONG_BUY
Consensus view from 16 analysts covering this stock
About Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

https://www.dyne-tx.com

Country: United States Employees: 263 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% N/A
Debt must be below 33% of total assets
Cash Ratio
0.0% N/A
Interest-bearing cash below 33% of assets
Receivables
0.0% N/A
Receivables below 49% of assets
Revenue Purity
0.0% N/A
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
MARKUP
Price trending up with increasing momentum
Sharpe Ratio
0.106
Positive but modest risk-adjusted returns
Kelly Fraction
0.0042
Marginal edge — very small allocation suggested
Calmar Ratio
-0.267
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-22.8%
Historical annualised return based on price data
Max Drawdown
-85.5%
Largest peak-to-trough decline — the worst it has been
HMM State
SIDEWAYS
Price consolidating — no clear directional bias
Days in State
36
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
1.08
Moves slightly more than the broader market
52W High
$25.00
32% below the year high
52W Low
$8.06
111% above the year low
Avg Volume
1,978,654
Average daily shares traded — higher means easier to buy and sell
Short Ratio
13.1
Days it would take all short sellers to cover — higher means more crowded
Short % Float
16.8%
Elevated short interest — bears are positioned against this
Div Yield
N/A
Annual dividend as a percentage of the share price
EPS (TTM)
$-3.15
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
19.50
Heavy leverage — higher financial risk if revenues decline
Current Ratio
19.92
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
18.97
Like current ratio but excludes inventory — stricter test
Gross Margin
0.0%
Revenue left after cost of goods — higher means pricing power
Operating Margin
0.0%
Profit from core operations before interest and tax
Free Cash Flow
$-292,282,240
Negative — the business is spending more than it generates
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
$-451,707,008
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
16
Target High
$50.00
Target Median
$39.50
Target Low
$17.00
Political Trading Activity

Congressional trading disclosures involving this instrument

Date Politician Party Type Amount
2025-01-15 Mark Green buy 15000
Source: Congressional disclosure filings. View all political trades at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.